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Abstract
Improved access to effective tests for diagnosing tuberculosis (TB) has been designated a public health priority by the World
Health Organisation. In high burden TB countries nucleic acid based TB tests have been restricted to centralised laboratories
and specialised research settings. Requirements such as a constant electrical supply, air conditioning and skilled, computer
literate operators prevent implementation of such tests in many settings. Isothermal DNA amplification technologies permit
the use of simpler, less energy intensive detection platforms more suited to low resource settings that allow the accurate
diagnosis of a disease within a short timeframe. Recombinase Polymerase Amplification (RPA) is a rapid, low temperature
isothermal DNA amplification reaction. We report here RPA-based detection of Mycobacterium tuberculosis complex (MTC)
DNA in ,20 minutes at 39uC. Assays for two MTC specific targets were investigated, IS6110 and IS1081. When testing
purified MTC genomic DNA, limits of detection of 6.25 fg (IS6110) and 20 fg (IS1081)were consistently achieved. When
testing a convenience sample of pulmonary specimens from suspected TB patients, RPA demonstrated superior accuracy to
indirect fluorescence microscopy. Compared to culture, sensitivities for the IS1081 RPA and microscopy were 91.4% (95%CI:
85, 97.9) and 86.1% (95%CI: 78.1, 94.1) respectively (n = 71). Specificities were 100% and 88.6% (95% CI: 80.8, 96.1)
respectively. For the IS6110 RPA and microscopy sensitivities of 87.5% (95%CI: 81.7, 93.2) and 70.8% (95%CI: 62.9, 78.7) were
obtained (n = 90). Specificities were 95.4 (95% CI: 92.3,98.1) and 88% (95% CI: 83.6, 92.4) respectively. The superior specificity
of RPA for detecting tuberculosis was due to the reduced ability of fluorescence microscopy to distinguish Mtb complex
from other acid fast bacteria. The rapid nature of the RPA assay and its low energy requirement compared to other
amplification technologies suggest RPA-based TB assays could be of use for integration into a point-of-care test for use in
resource constrained settings.
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Introduction
Tuberculosis (TB) is an infectious disease that is very often
difficult to diagnose. The World Health Organisation (WHO)
estimates that during 2012 the global case detection rate for TB
was 66%, suggesting that of the estimated 8.6 million incident
cases that year almost 3 million cases were not diagnosed and
notified [1]. Pulmonary TB, the most infectious form of the
disease, is diagnosed by detecting Mycobacterium tuberculosis
complex (MTBC) bacilli in samples of sputum expectorated by the
patient. Smear microscopy, which is the primary test used for the
diagnosis of pulmonary TB endemic countries [1], is a laborious
and relatively insensitive test with a case detection rate of only 56
to 68% [2]. While microscopy can diagnose late stage TB disease,
it performs poorly on specimens acquired from cases with HIV co-
infection due to the reduced numbers of TB cells produced in a
sputum specimen. Failure to detect and treat pulmonary disease in
a timely manner results in onward transmission and the
continuation of the epidemic which claimed an estimated 1.2
million lives during 2012 [1]. The WHO recently noted that in
2012 approximately three million cases of active TB went
undiagnosed by country programs [1] and there is a pressing
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need for improved diagnostic tools to supplant smear microscopy
to facilitate rapid detection [3,4].
To this aim, the Xpert MTB/RIF (Cepheid, USA) was
endorsed by WHO in 2010 to detect pulmonary disease in
settings with a high incidence of TB/HIV co-infection or with
high rates of drug resistance [5]. This polymerase chain reaction
(PCR) based test is fully integrated into a modular system and can
detect both TB infection and indicate the presence of resistance to
one of the key anti-tuberculosis drugs, rifampicin. The key
attribute of the GeneXpert system is its ease of use, as the
majority of key processes are integrated and automated from DNA
extraction to interpretation of a test result [6]. However, the
GeneXpert requires consistent electricity and laboratory temper-
atures maintained under 30uC, which poses logistical challenges
[7]. Furthermore, the cost of cartridges, instrumentation and
maintenance threaten its sustainability in the longer term in high
TB burden countries that currently rely on global donor assistance
to provide this technology. Therefore, to increase access to timely
and accurate diagnosis for more TB suspected patients, rapid, high
performance TB diagnostic tests that can meet the logistical
challenges of unsupervised use in limited infrastructure settings are
required and at a price that is more comparable to smear
microscopy [3,8–10]. Other technologies have been developed for
TB diagnosis in microscopy centers in high burden countries and
are currently undergoing evaluation. These include semi-modular
systems (Epistem Genedrive and Molbio EASYNAT) or methods
with manual specimen processing and test determination (Eiken
LoopAMP TB and Ustar Biotechnologies Easy NAT) [9,11–15].
Recently, isothermal amplification assays utilizing loop mediat-
ed amplification (LAMP), helicase dependant amplification (HDA)
and cross priming amplification (CPA) have been described for the
diagnosis of pulmonary TB [12,16,17]. Unlike PCR, isothermal
assays do not require precisely controlled thermal cycling and
instead use only a uniform incubation temperature, typically 55–
65uC, to permit DNA amplification and therefore may offer
greater utility with more simplistic reactor designs or heat sources
[12,18–20]. Recombinase Polymerase Amplification (RPA) has
emerged as a novel, isothermal technology for use in molecular
diagnosis of infectious disease [21]. Unlike many other isothermal
technologies, RPA does not require elevated or precise temper-
atures, and may proceed at temperatures between 25uC and 42uC
[21]. RPA replaces the thermal cycling needed for PCR with three
core enzymes. The titular enzyme, a recombinase, binds to
oligonucleotide primers to form recombination filaments that can
recombine with homologous DNA (Figure 1). The second enzyme,
a single-stranded DNA binding protein, binds to the strand of
DNA displaced by the primer, stabilising the D-loop that has
formed and preventing the dissociation of the primer. The third
core enzyme is a strand-displacing DNA polymerase that copies
the DNA template by adding bases onto the 39 end of the primer,
forcing open the DNA double helix as it progresses. As with PCR,
the use of closely spaced opposing primers allows the exponential
amplification of a defined region of DNA. RPA reactions typically
run to completion in 5–15 minutes, depending on amplicon size
and the template copy number [21]. This time to test result is
significantly more rapid than the other isothermal MTBC assays
which note incubation times in the range of 45–60 minutes
[12,13,16].
The highly specific detection of RPA products is achieved via
the use of custom designed oligonucleotide probes which recognize
a complementary region within either strand of the RPA
amplicon. The probe DNA is also inserted via a recombinase
mediated event. RPA probes are constructed with an abasic
nucleotide analogue within the probe sequence. This abasic site is
recognised and cleaved by several types of endo- or exonucleases,
but only when the probe has bound to its complementary
sequence. Different nucleases are specifically added to the core
RPA reaction mixture for use in a variety of detection formats,
including fluorescence detection in real time or endpoint detection
via a lateral flow strip [21,22]. Reverse transcriptase, can be also
included in RPA reactions to facilitate RPA from RNA targets
such as Middle East Respiratory Syndrome Coronavirus or Rift
Valley Fever [23,24]. Recently RPA was been demonstrated to be
highly sensitive for the detection of HIV proviral DNA [22] and in
this work we have investigated the use of RPA to detect
Mycobacterium tuberculosis DNA from patients presenting with
suspected pulmonary TB.
Materials and Methods
RPA assay design
Oligonucleotide primers and probes used to develop the RPA
assays were purchased from Eurogentec Ltd (Southampton, UK)
and Biosearch Technologies (Novato, CA) respectively. Prelimi-
nary screening of primer and probe combinations used the Twist
Amp Exo kits according to the manufacturer’s instructions
(TwistDx Ltd., UK) in final reaction volumes of 50 mL. The
RPA reactions were incubated at 39uC using a combined heating
and fluorescence detection device (Twista, TwistDx, UK) [22].
Samples were mixed prior to amplification and also at six minutes
during incubation. The output of the RPA reaction was monitored
in real time using Twista Studio Software (TwistDx, UK) with
fluorescence measurements taken every 20 seconds for a total of
20 minutes.
Once optimal primer and probe sequences were identified,
lyophilized pellets of the TwistAmp Exo reactions were prepared
that also contained the primers and probe. For 50 mL reactions,
4 mL of 280 mM MgOAc, 37.5 mL TwistAmp Primer-In-Pellet
Resuspension Buffer (PIRB, TwistDx Ltd) and 8.5 mL of sample/
water were used to rehydrate the pellets. Double amounts of
reagent were used for 100 mL reactions. Sample incubation
conditions remained the same as used for primer screening.
DNA Samples
Cultures of M. tuberculosis (H37Rv) and M. bovis BCG-
Bulgaria (BB-NCIPD Ltd., Bulgaria) were maintained on Low-
enstein Jensen slants supplemented with glycerol (Media for
Mycobacteria, UK) and Middlebrook 7H9 media supplemented
with 10% ADC (BD BBL, USA). DNA was extracted using the
standardised RFLP protocol and quantified using the Qubit
platform (Invitrogen, Life Technologies Ltd. UK) [25]. Samples of
purified DNA from non tuberculous mycobacteria (NTM) were
supplied by the Mycobacteriology Unit (Institute of Tropical
Medicine, Antwerp, Belgium [Table 1]). DNA concentrations
were quantified using the Qubit platform (Invitrogen, Life
Technologies Ltd. UK) and 500 pg (,114,000 genomes) samples
in a volume of 1 mL were added to the RPA reactions. Using the
molecular weight per genome as determined from the whole
genome sequence of the BCG Tokyo 172 strain (Accession #:
224771496) we calculate that 5 fg of BCG DNA correlates to an
estimated genome equivalent (GE) of one cell [26]. A second panel
of fully characterized NTM strains and other bacteria including
common respiratory pathogens were accessed from the reference
collection of the Washington State Public Health Laboratory
(Table 1). Crude genomic DNA extracts were prepared as
described previously [27].
Rapid Detection of M. tuberculosis by RPA
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e103091
Clinical samples
An evaluation of the RPA assay was performed using a panel of
sputum and respiratory specimens derived from suspected cases of
pulmonary TB obtained from the Washington State Public Health
Laboratories. Samples tested by RPA were remains of specimens
collected for routine diagnosis and were not representative of the
population attending the clinic having been selected to provide a
panel with an unusually high proportion of positive samples. Study
investigators were blinded to the status of the samples. The panel
comprised 121 specimens including induced and expectorated
sputum (n= 119) and respiratory washes (bronchial and tracheal,
n = 2) collected from a total of 101 TB suspect cases (no more than
two specimens per individual were tested). Specimens were
processed via digestion and decontamination using the N-acetyl
L-cysteine NaOH-Na citrate method [28]. For each specimen,
cells were pelleted by centrifugation at 60006 g and the
supernatant was discarded. Each pellet was then resuspended in
1.5 mL of sterile phosphate-buffered saline (PBS, pH 6.8). Smears
were prepared from the decontaminated specimens to determine
the presence acid fast bacteria using Auramine O and fluorescence
microscopy. A specimen was considered smear positive if greater
than 1 AFB was present per 10 observed microscopic fields. The
smear positive specimens were scored from +/2 (scanty), 1+ to 4+
based on the number of observed AFB positive cells present [28].
Culture was performed using MGIT modified Middlebrook
7H-9 liquid medium in an automated BACTEC 460TB System
(Becton, Dickinson and Company, New Jersey, USA) with
incubation at 37uC for up to 1 month. A 0.5 mL inoculum of
processed specimen was used per mycobacterial culture. All
positive cultures were then screened for MTBC using the
Mycobacterium Tuberculosis Complex Culture Identification
Test (Gen-Probe, San Diego, CA) according to the manufacturer’s
instructions. The MTBC negative culture positive isolates were
speciated by additional biochemical testing. A 250 mL aliquot of
each processed specimen was used for DNA extraction. A
previously described extraction process using glass beads and heat
lysis was used, the lysed samples were then stored at 220uC until
use [27]. The specimens screened by RPA TB assays were
prepared as described earlier. Each RPA reaction contained 5 mL
of specimen extract added with rehydration buffer, MgOAc and
molecular grade water to create a final reaction volume of 50 mL.
Scoring of positive RPA reactions incubated in the Twista RPA
reactor was indicated by an increase in FAM fluorescence by
greater than 300 mV from six to twenty minutes incubation.
The clinical materials used in this study were discarded remains
of specimen collected for routine diagnostic examination, all data
was blinded with no links to enable identification of patients. As
such, the study was exempt from ethical approval in accordance
with US Code of Federal Regulations 45 CFR 46.101. Work in
Figure 1. DNA amplification by Recombinase Polymerase Amplification. The three core proteins, recombinase, single-strand DNA binding
protein (SSB) and strand-displacing polymerase enable PCR-like DNA amplification without the need for thermal cycling or an initial chemical or
thermal melting step. This diagram was created by TwistDx Ltd (http://www.twistdx.co.uk/our_technology/) and is licensed under a Creative
Commons Attribution 3.0 United States License.
doi:10.1371/journal.pone.0103091.g001
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the UK was approved by the Research Ethics Committee of the
London School of Hygiene & Tropical Medicine and was
undertaken in compliance with the Human Tissue Act (2004).
Results
Design of RPA assays for IS6110 and IS1081
An RPA assay was designed to target the insertion sequence,
IS6110 [29,30], a region that has been shown to have high
sensitivity for diagnosing tuberculosis using PCR [31,32]. IS6110
is often present inM. tuberculosis in multiple copies of up to 25 per
genome [33] but conversely MTBC isolates with no IS6110 target
have also been described [34,35]. Mycobacterium bovis bacillus
Calmette-Gue´rin (BCG) strains have a low number of IS6110
copies, the Bulgarian BCG strain used in this study having two
copies [36]. To ensure coverage of all MTBC species, an second
RPA assay for the insertion sequence IS1081 was also developed
[37]. Unlike IS6110, IS1081 is present in all MTBC species and
at a more stable copy number of 5–7 repeats per genome [38], the
Bulgarian BCG strain used in this study having six copies. The
primers and probes for both the IS6110 and IS1081 assays were
selected based upon sequences described for the MTB H37Rv
whole genome (NCBI Reference Sequence: NC_000962.3 [39])
and M. bovis BCG [37]. All initial designs were then screened
Table 1. Strains used for specificity testing.
M. absessus ATCC 19977 M. mageritense 981294 Arcanobacterium hemolyticum
M. aurum ATCC 23366* M. malmoense ATCC 29571 Bordetella cepacia ATCC 25410
M. avium 961091* M. malmoense 40445* B. pertussis
M. avium ATCC 25291 M. marina ATCC 927 B. bronchiseptica ATCC 19395
M. brisbanense M. marinum1717 Corynebacterium striatum
M. catarrhalis M. nebraskense Escherichia coli ATCC 25922
M. chelonae M. neoaureum 40853 Gordonia bronchialis
M. chelonae 41426 M. nonchromogenicum 970454* Haemophilus influenzae
M. chitae ATCC 19628* M. nonchromogenicum ATCC 19530 Legionella pneumophilia ATCC 33152
M. diernhoferi ATCC 19340* M. parafinicum 3098* Neisseria meningitidis ATCC 13077
M. fortuitum ATCC 6841 M. peregrinum Pseudomonas aeruginosa
M. gordonae ATCC 14470 M. peregrinum 10086* Rhodococcus equi
M. gordonae10284 M. poriferae ATCC 35087 Staphylococcus aureus ATCC 29213
M. heidelbergense 981295* M. scrofulaceum ATCC 19073* Streptococcus agalactiae ATCC 27591
M. immunogen 981291* M. shimodei 27962* S. anginosus ATCC 33397
M. intracellulare 32665* M. simiae ATCC 25273 S. pneumoniae ATCC49619
M. intracellulare ATCC 13950 M. smegmatis mc2155* S. pyogenes ATCC 12370
M. intracellulare ATCC 35761 M. szulgai ATCC 35799 S. salivarus
M. kansasii M. szulgai 4981* Yersinia pseudotuberculosis ATCC 23207
M. kansasii ATCC 12478 M. ulcerans 5147
M. kansasii MYC 4296 M. xenopi
M. lentifalvum 960190* M. xenopi 9741*
M. liflandi 40413*
Non-tuberculous mycobacterial (NTM) strains and other bacterial species used in the determination of the specificity of the IS6110 and IS1081 RPA assays. All tested
negative by both RPA assays. Isolates marked * were supplied by the Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium. All other isolates were
from the Washington State Public Health Laboratory strain collection.
doi:10.1371/journal.pone.0103091.t001
Table 2. Oligonucleotide primers and probes.
Oligonucleotide Sequence (59 R 39)
IS6110c_Forward GATCCTGCGAGCGTAGGCGTCGGTGACAAAGGCCACGTAG
IS6110c_Reverse CTGATCCGGCCACAGCCCGTCCCGCCGATCTCGTCCAGC
IS6110c_Probe CGAACCCTGCCCAGGTCGACACATAGGTGAGGTC(F)(H)C(Q)ACCCACAGCCGGTTA-Spacer C3
IS1081a_Forward CAGTAGTGGGCGGTCATCGCGTGATCCTTCGAAACGACC
IS1081a_Reverse CTCGCCTGTGCGAGTTGGTCAGCCAGAAGCTG
IS1081a_Probe CGATAAGATGAGAAGAGGTCATTGCGTCATT(F)(H)C(Q)TCGATTGACTTTTGCT-Spacer C3
The oligonucleotides chosen for amplification and detection of IS6110 and IS1081 are shown in Table 2. F = dT-FAM, H= tetra hydrofuran and Q=dT-Black Hole
Quencher 1.
doi:10.1371/journal.pone.0103091.t002
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Figure 2. Real-time RPA amplification of IS1081 and IS6110. Figure 2a shows the real time detection of IS1081 amplification from a dilution
series of quantitated M. bovis BCG DNA with a sensitivity as low as 0.04 pg of DNA per reaction. Figure 2b shows the real time detection of IS6110
amplification from a dilution series of quantitated M. bovis BCG DNA BCG DNA with a sensitivity as low as 5.0 fg of DNA per reaction.
doi:10.1371/journal.pone.0103091.g002
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using BLASTN and the NCBI nucleotide database to ensure the
target sequences for the primers and probes were exclusive to
MTBC species only [40]. The only difference between RPA
primers and PCR primers is one of length, with 30–38 base
oligonucleotides being optimal for the formation of efficient
recombinase filaments. TwistAmp exo probes are oligonucleotides
that are typically 46–52 bases long, with a tetra-hydrofuran (THF,
sometimes referred to as a dSpacer) creating an abasic site in the
oligonucleotide probe sequence [21]. The THF is positioned $30
bases from the 59 end and $15 bases from the 39 end. A
fluorophore and a quencher are positioned on either side of the
THF moiety, typically 2–4 bases apart. The only commercially
available labelled phosphoramidite bases are dT and so the
location of T nucleosides dictates the precise location of probes.
The 39 ends of each probe are blocked with a C3-spacer to prevent
DNA polymerase extension from undigested probes. However,
after exonuclease III digestion at the abasic site within the Exo
probe, the newly generated 39 end of the larger portion of the
cleaved probe has a hydroxyl group from which DNA polymerase
mediated strand extension can then occur.
Once probes had been selected, ten 35 mer primers were
chosen at 5 base intervals (30 base overlap) upstream and
downstream of the target regions for screening with 50 copies of
TB DNA. Screening was performed with TwistAmp Exo
reactions. After the initial screens, the primers that gave the best
amplification of target DNA were then redesigned as a series of
staggered primers with single base intervals deviating from the
original primer sequence. These sets were then screened in in an
effort to identify if any produced a faster time to result from 50
copies of template DNA. A third and final round of primer
screening was performed with different length (30–38 bases,
varying at the 39 end) versions of the best primers. Figure S1 shows
how this screening can improve performance of an assay. The
oligonucleotides selected to amplify IS6110 and IS1081 are listed
in Table 2.
Analytical sensitivity of RPA
The sensitivity of the RPA reactions were assessed by testing
serial dilutions of genomic DNA extracted from M. bovis BCG.
Multiple tests were performed at each concentration of DNA, with
water used as a negative control (Table 3). An example of the
output is shown in Figures 2a and 2b. The time to onset of a rise in
fluorescence increased as the amount of BCG genomic DNA in
the sample decreased. When using IS6110 primers, 6.25 fg per
100 mL reaction were required for reactions to be consistently
positive, which is approximately equivalent to the DNA found in a
single bacteria (n = 9). As shown in figure 2b, when testing low
levels of DNA the time to onset of fluorescence was associated with
the amount of DNA in the samples, with 11 min being required
when testing 5 fg. When using IS1081 primers consistent positive
results were obtained for all samples containing at least 20 fg BCG
genomic DNA (Table 3). The time to onset of signal at the lowest
concentration of 20 fg ranged from 7 to 9 minutes. These results
suggested that either RPA assay is highly sensitive for the rapid
amplification and detection of MTBC DNA, and that a 15 minute
data collection period is sufficient to detect positive samples.
Sensitivity was also assessed by testing replicate serial dilutions of a
culture of BCG. Results (not shown) indicated that both RPA
assays were capable of detecting a single colony forming unit of
bacteria.
Specificity of RPA
To assess the specificity of the IS6110 and IS1081 RPA
reactions for the identification of MTBC, samples of DNA from a
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panel of 23 non tuberculous mycobacteria (NTMs) were tested
(Table 1). Positive controls using 500 pg DNA from either M.
bovis BCG or M. tuberculosis H37Rv were used for each batch.
No signals were obtained from the bacterial DNAs other than the
MTBC strains, indicating high specificity for the primers used. In
a second round of screening to challenge the RPA TB assay’s
specificity, genomic DNA from a further 25 NTMs and 19 non-
mycobacterial species was used (Table 1). The crude DNA
extracts derived from cultured bacteria indicated no cross
reactivity with RPA assay for any bacterial species further
confirming the high specificity of the IS6110 and IS1081 assays
across a broad range of NTMs, or more divergent bacterial
species.
Assessment of RPA performance using clinical specimens
IS6110 RPA assay. The specimen panel used to assess RPA
assay performance was biased in its construction to reflect
approximately 50% MTBC positive and 50% MTBC negative
samples respectively, based on liquid culture results with subse-
quent pathogen identification. Fifty-six specimens were culture
positive and of these forty-five were confirmed as MTBC positive
after confirmation via Accuprobe testing (Table S1). The
remaining eleven cultures were further identified as NTMs.
Thirty-one specimens were culture negative and three cultures
were contaminated (See Table S1). For these three, new specimens
were acquired, and all three were later confirmed as MTBC
positive by culture and Accuprobe. Smear microscopy results for
this panel observed AFB ranging from 4+ to scanty for thirty-nine
specimens while fifty-one were smear negative [41]. From this
panel forty-four samples were found positive by RPA (Table 4,
Table S1) and the sensitivity and specificity of the IS6110 RPA
assay when compared to confirmed culture were 87.5% (95% CI:
81.7,93.2) and 95.4 (95% CI: 92.3,98.1) respectively. The indirect
smear microscopy was less accurate at 70.8% (95% CI: 62.91,
78.75) and 88% (95% CI: 83.6, 92.4). The IS1081 RPA assay
detected 100% of smear positive TB samples, and 8/14 (57.1%;
95%CI: 33.8, 80.4) of the smear negative culture confirmed TB
specimens (Table 5, Table S1). Four NTMs were found smear
positive but RPA negative.
IS1081 RPA assay. The panel used to assess the performance
of the IS1081 RPA assay also contained a disproportionately high
number of MTBC positive specimens. A total of 71 specimens
previously characterized by smear microscopy and culture were
used. Due to limited access to clinical materials only forty of the
specimens used in the IS6110 assay evaluation were also used to
evaluate the IS1081 RPA assay. The remaining 31 isolates were
only screened with the IS1081 RPA assay. The panel used
contained 47 culture positive samples of which 35 were confirmed
as MTBC via Accuprobe, and 12 as NTMs (Table 4, Table S1).
The remaining 24 samples were culture negative. According to
smear microscopy data, this panel contained 36 smear positive
specimens ranging from 4+ to scanty (+/2). From this panel 32
samples were found positive by RPA (Table 4, Table S1) and the
sensitivity and specificity of the IS1081 RPA assay when
compared to confirmed culture were 91.4% (95% CI: 85,98.9)
and 100% respectively. The indirect smear microscopy was less
accurate at 86.1% (95% CI: 78.1, 94.1) and 88.6% (95% CI: 80.8,
96.1). RPA detection of smear positive TB samples was 96.8% and
2/5 (40%; 95%CI: 0,98.8) of the smear negative samples from
culture confirmed TB patients were detected. Four NTMs were
found smear positive but RPA negative.
Discussion
In this study we have demonstrated the application of RPA to
diagnosis TB from sputum. Two assays targeting separate
repetitive elements were examined, both demonstrating the ability
to detect MTBC DNA with a high degree of sensitivity and
specificity in less than 20 minutes. Of the two assays the IS6110
RPA consistently detected ,6.5 fg of genomic DNA, and thus
Table 4. Tuberculosis detection by indirect smear microscopy vs RPA IS6110.
Culture positive Culture negative
Indirect smear microscopy positive 34 5
Indirect smear microscopy negative 14 37
RPA IS6110 positive 42 2
RPA IS6110 negative 6 40
Testing pulmonary specimens (n = 90) by indirect smear microscopy and RPA IS6110 to detect tuberculosis, with comparison to liquid culture based test data. RPA
IS6110 was more sensitive than indirect smear microscopy (87.5% (95% CI: 81.7, 93.2) vs 70.8% (95% CI: 62.91, 78.75)) and also more specific (95.4 (95% CI: 92.3, 98.1) vs
88% (95% CI: 83.6, 92.4)).
doi:10.1371/journal.pone.0103091.t004
Table 5. Tuberculosis detection by indirect smear microscopy vs RPA IS1081.
Culture positive Culture negative
Indirect smear microscopy positive 31 4
Indirect smear microscopy negative 5 31
RPA IS1081 positive 32 0
RPA IS1081 negative 4 35
Testing pulmonary specimens (n = 71) by indirect smear microscopy and RPA IS1081 to detect tuberculosis, with comparison to liquid culture based test data. RPA
IS1081 was more sensitive than indirect smear microscopy (91.4% (95% CI: 85,98.9) vs 86.1% (95% CI: 78.1, 94.1)) and also more specific (100% vs 88.6% (95% CI: 80.8,
96.1)).
doi:10.1371/journal.pone.0103091.t005
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could detect samples estimated to contain the genome equivalent
of a single bacterial cell. The IS1081 assay required slightly higher
amounts of DNA 20 fg, which was not expected as it does not
reflect the increased number of copies of this insertion element in
the genome (six IS1081 vs two IS6110). We suspect the lower
sensitivity observed is due to reduced primer and probe binding
efficiency of the oligonucleotides screened in this study. We also
cannot rule out the possibility of localized secondary or tertiary
DNA structures affecting the recombinase mediated insertion of
the oligonucleotides despite the presence of high levels of ssDNA
binding protein in RPA reactions. Nonetheless both assays
demonstrated the potential of RPA as a diagnostic tool to detect
tuberculosis in samples containing low numbers of bacteria. Both
assays were shown to be highly specific for MTBC (100%) when
challenged with acid fast bacterial species that do not cause
tuberculosis or 18 other common commensal or respiratory
bacterial pathogens.
When the performance RPA was assessed with clinically derived
specimens, we found that both assays had high sensitivity (100%)
with isolates that were smear and culture positive. For samples that
were smear negative but culture positive 8/14 (57.1%) and 2/5
(40%) were identified as positives via the IS6110 and IS1081
assays, respectively. It should be noted a crude DNA extraction
procedure was used and improved sample handling and DNA
extraction may improve detection from complex sample matrixes
such as sputum [42]. Similarly whereas 0.5 ml inoculums were
used for culture the volume taken for DNA extraction was only
0.25 ml, with just 5 mL being used for each RPA assay and there
may be opportunity to improve sensitivity by testing larger sample
volumes or by incorporating a sample concentration step. To fulfil
the full potential of RPA for point-of-care diagnostics, an
integrated platform to perform sample preparation and run the
assay must be developed.
Further work is required to optimize specificity of RPA for TB
diagnosis from clinical samples. In particular the number of
negative samples included in this study were insufficient to assess
the clinical specificity and the number of culture-positive, smear-
negative samples should be increased to better determine the
clinical sensitivity. Ten of ten NTM positive specimens were
correctly assigned by the IS1081 assay as being MTBC negative,
demonstrated a specificity of 100%. However, whereas the IS6110
assay correctly assigned two NTM specimens as negative two false
positives were observed for smear negative specimens that were
culture positive for NTM. The positive predictive value (PPV) and
negative predictive value (NPV) are not presented as the contrived
composition of the MTBC screening panels used in this study were
selected to demonstrate proof of concept and do not reflect the
normal distribution of specimens received for routine screening of
pulmonary MTBC infection [43].
In this study we have provided an evidence base for RPA as a
tool for the rapid and sensitive detection of DNA from MTBC.
The comparatively low isothermal incubation temperature com-
bined with rapid time to result allows RPA to be used with a
battery powered device, making it amenable to health clinics in
developing countries that do not have reliable electricity supply
[44]. However, further studies are required to adapt sample
extraction methodology for use at the point of care.
Supporting Information
Figure S1 Benefits of RPA primer optimisation. This
figure shows a side-by-side comparison of duplicates of the optimal
primer pairs chosen during each round of screening for IS6110
with either 50 (dotted lines) or 500 (solid lines) copies of template.
The primers chosen at the end of the first round of screening
(purple, ‘Round 1’), can detect both 50 and 500 copies of template.
The optimal primers identified by shuffling these primers
upstream and downstream in single base increments (red,
‘Shuffled’) give faster detection times and result in higher levels
of fluorescence. The primers chosen from lengthening and
shortening the 39 end of these shuffled primers (green, ‘Length’)
show further improvement to detection time and fluorescent
signals. Note that in all instances, poor duplicates are often
indicative that an assay is close to its limit of detection.
(TIF)
Table S1 Culture, smear and RPA test results derived
from clinical specimens. The scores for bacteria counted in
the smear +ve specimens are shown in parenthesis, e.g. +ve (2+).
Smear scores that were scanty are shown as +/2. Acronyms and
other points. MTBC – Mycobacterium tuberculosis complex; NT
– Not Tested; NTM = - Non Tuberculous Mycobacteria. MTBC.
* Primary culture was contaminated; specimen was confirmed via
a fresh specimen; # bronchoalveolar lavage (others not marked
are sputum).
(DOCX)
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